Proprietary Name Review(s)

13

Transcript of Proprietary Name Review(s)

Page 1: Proprietary Name Review(s)
Page 2: Proprietary Name Review(s)
Page 3: Proprietary Name Review(s)
Page 4: Proprietary Name Review(s)
Page 5: Proprietary Name Review(s)
Page 6: Proprietary Name Review(s)
Page 7: Proprietary Name Review(s)
Page 8: Proprietary Name Review(s)
Page 9: Proprietary Name Review(s)
Page 10: Proprietary Name Review(s)
Page 11: Proprietary Name Review(s)
Page 12: Proprietary Name Review(s)
Page 13: Proprietary Name Review(s)

PROPRIETARY NAME REVIEW(S)...analysis studies consisting of two written prescription studies (inpatient and outpatient) and one verbal prescription study, involving healthcare practitioners

PROPRIETARY NAME REVIEW(S)...analysis studies consisting of two written prescription studies (inpatient and outpatient) and one verbal prescription study, involving healthcare practitioners

Proprietary Name Review(s) · 2019. 12. 4. · review on December 14, 2018. 1.2 PRODUCT INFORMATION The following product information is provided in the proprietary name submission

Proprietary Name Review(s) · 2019. 12. 4. · review on December 14, 2018. 1.2 PRODUCT INFORMATION The following product information is provided in the proprietary name submission

204427Orig1s000 - Food and Drug Administration · center for drug evaluation and research application number: 204427orig1s000 proprietary name review(s)

204427Orig1s000 - Food and Drug Administration · center for drug evaluation and research application number: 204427orig1s000 proprietary name review(s)

125418Orig1s000 - Food and Drug Administration...125418Orig1s000 PROPRIETARY NAME REVIEW(S) 4 of 4 ... Stedman's Medical Dictionary, 26th ed. 1995, at 1292. Reference ID: 3165699 (b)

125418Orig1s000 - Food and Drug Administration...125418Orig1s000 PROPRIETARY NAME REVIEW(S) 4 of 4 ... Stedman's Medical Dictionary, 26th ed. 1995, at 1292. Reference ID: 3165699 (b)

PROPRIETARY NAME AND DOSAGE FORM

PROPRIETARY NAME AND DOSAGE FORM

Novo Nordisk's Victoza FDA CDER Proprietary Name Review

Novo Nordisk's Victoza FDA CDER Proprietary Name Review

Proprietary Name Review(s)...2019/02/19  · 2.2.8 Communication of DMEPA’s Analysis at Midpoint of Review DMEPA communicated our findings to the Division of Oncology Products 2

Proprietary Name Review(s)...2019/02/19  · 2.2.8 Communication of DMEPA’s Analysis at Midpoint of Review DMEPA communicated our findings to the Division of Oncology Products 2

Bortezomib Hospira International non-proprietary name ... · Committee for Medicinal Products for Human Use (CHMP) Assessment report . Bortezomib Hospira . International non-proprietary

Bortezomib Hospira International non-proprietary name ... · Committee for Medicinal Products for Human Use (CHMP) Assessment report . Bortezomib Hospira . International non-proprietary

[INSERT YOUR NAME HERE] Campaign Overview. Proprietary and Confidential2 The Problem.

[INSERT YOUR NAME HERE] Campaign Overview. Proprietary and Confidential2 The Problem.

VETERINARY DRUG USE AND PRESCRIBING CH. 5. –All drugs have 3 names Chemical name Generic (nonproprietary) name Trade (proprietary) name.

VETERINARY DRUG USE AND PRESCRIBING CH. 5. –All drugs have 3 names Chemical name Generic (nonproprietary) name Trade (proprietary) name.

205787Orig1s000 - Food and Drug Administration · 205787Orig1s000 PROPRIETARY NAME REVIEW(S) Department of Health and Human Services Public Health Service . Food and Drug Administration

205787Orig1s000 - Food and Drug Administration · 205787Orig1s000 PROPRIETARY NAME REVIEW(S) Department of Health and Human Services Public Health Service . Food and Drug Administration

Report on the Deliberation Results4 Review Report (1) June 28, 2013 I. Product Submitted for Registration [Brand name] Vyndaqel Capsules 20 mg [Non-proprietary name] Tafamidis Meglumine

Report on the Deliberation Results4 Review Report (1) June 28, 2013 I. Product Submitted for Registration [Brand name] Vyndaqel Capsules 20 mg [Non-proprietary name] Tafamidis Meglumine

PDUFA Pilot Project: Proprietary Name Review · PDF fileConcept Paper PDUFA Pilot Project Proprietary Name Review I. INTRODUCTION On September 27, 2007, President Bush signed into

PDUFA Pilot Project: Proprietary Name Review · PDF fileConcept Paper PDUFA Pilot Project Proprietary Name Review I. INTRODUCTION On September 27, 2007, President Bush signed into

APPLICATION NUMBER: 21-983 PROPRIETARY NAME REVIEW(S)€¦ · APPLICATION NUMBER: 21-983 PROPRIETARY NAME REVIEW(S) FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research

APPLICATION NUMBER: 21-983 PROPRIETARY NAME REVIEW(S)€¦ · APPLICATION NUMBER: 21-983 PROPRIETARY NAME REVIEW(S) FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research

210737Orig1s000 210737Orig2s000 PROPRIETARY NAME ......Thus, Cumberland Pharmaceuticals Inc. resubmitted the proposed proprietary name, RediTrex, for review. 2 METHODS AND DISCUSSION

210737Orig1s000 210737Orig2s000 PROPRIETARY NAME ......Thus, Cumberland Pharmaceuticals Inc. resubmitted the proposed proprietary name, RediTrex, for review. 2 METHODS AND DISCUSSION

SCHEDULING STATUS PROPRIETARY NAME AND DOSAGE FORM …€¦ · 08-04-2020  · PROPRIETARY NAME AND DOSAGE FORM . BOTOX® vacuum-dried injection. COMPOSITION . BOTOX® (Botulinum

SCHEDULING STATUS PROPRIETARY NAME AND DOSAGE FORM …€¦ · 08-04-2020  · PROPRIETARY NAME AND DOSAGE FORM . BOTOX® vacuum-dried injection. COMPOSITION . BOTOX® (Botulinum

Caelyx, INN-doxorubicin hydrochloride · 2 Invented name/Name: Caelyx International non-proprietary name/Common name: doxorubicin hydrochloride Extension of the indication to include:

Caelyx, INN-doxorubicin hydrochloride · 2 Invented name/Name: Caelyx International non-proprietary name/Common name: doxorubicin hydrochloride Extension of the indication to include:

PROPRIETARY NAME REVIEW(S) · 2.2.1 United States Adopted Names (USAN) Search There is no USAN stem present in the proposed proprietary name.4 2.2.2 Components of the Proposed Proprietary

PROPRIETARY NAME REVIEW(S) · 2.2.1 United States Adopted Names (USAN) Search There is no USAN stem present in the proposed proprietary name.4 2.2.2 Components of the Proposed Proprietary

International Non-proprietary Name: Leflunomide Procedure No: EMEA

International Non-proprietary Name: Leflunomide Procedure No: EMEA

Janage proprietary drug name personality profile-2

Janage proprietary drug name personality profile-2